e-learning
resources
Munich 2014
Monday, 08.09.2014
New clinical evidence for asthma and COPD treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Y. Ishii, A. Takemasa, K. Chibana, R. Arai, T. Shiobara, T. Watanabe (Mibu, Japan)
Source:
International Congress 2014 – New clinical evidence for asthma and COPD treatments
Session:
New clinical evidence for asthma and COPD treatments
Session type:
Thematic Poster Session
Number:
2417
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Ishii, A. Takemasa, K. Chibana, R. Arai, T. Shiobara, T. Watanabe (Mibu, Japan). Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD. Eur Respir J 2014; 44: Suppl. 58, 2417
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Differences in adherence to common inhaled medications in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept